Table 4. In vitro comparative fungicidal activity of T11F alanine-substituted derivatives against Candida albicans SC5314.
| Anti-Candida activity | ||||
| asd1 | M.M. (Da) | %* | EC50 **(95% confidence intervals) [mol/liter]×10−6 | EC50 asd/EC50 T11F |
| T1A | 1274.45 | 100 | 0.738 (0.711–0.766)§ | 0.48 |
| C2A | 1272.41 | 79.32 | 32.521 (25.220–41.944)§ | 21.12 |
| R3A | 1219.37 | 97.61 | 13.458 (12.146–14.909)§ | 8.74 |
| V4A | 1276.42 | 100 | 1.134 (1.083–1.188)§ | 0.74 |
| D5A | 1260.47 | 100 | 0.395 (0.389–0.402)§ | 0.26 |
| H6A | 1238.41 | 100 | 10.417 (9.948–10.901)§ | 6.76 |
| R7A | 1219.37 | 100 | 12.055 (11.498–12.646)§ | 7.83 |
| G8A | 1318.50 | 100 | 1.551 (1.465–1.642) | 1.01 |
| L9A | 1262.39 | 100 | 1.753 (1.679–1.830)§ | 1.14 |
| T10A | 1274.45 | 100 | 0.850 (0.844–0.854)§ | 0.55 |
| F11A | 1228.38 | 100 | 2.519 (2.433–2.607)§ | 1.64 |
1
asd, alanine-substituted derivative; M.M., molecular mass (dalton);
*
% inhibitory activity at 100 µg/ml in comparison to the control growth (water);
**
EC50, half maximal effective concentration.
§
Anti-Candida activity significantly different from that of T11F peptide as assessed by t test (P<0.001, except in the case of L9A, P = 0.0098).